1. Scrip
  2. >>Business
  3. >>Deals

UCB Assessing Bepranemab’s Future After Roche/Genentech Ends Partnership

Tau-Targeting Collaboration Dated Back To 2020

 
• By Mandy Jackson

UCB is evaluating next steps for bepranemab, for which it will soon present Phase IIa data at CTAD, after Genentech terminated a four-year partnership to develop the tau-targeting antibody.

Phase IIa data in prodromal and mild Alzheimer's disease will be presented at CTAD (Shutterstock)

UCB SA said in its 22 October announcement about a near-term presentation of Phase IIa results for bepranemab that the company has regained all rights to the tau-targeting antibody from Roche Holding AG/Genentech Inc., marking the end of a four-year collaboration around the Alzheimer’s disease candidate.

Key Takeaways

Roche’s Genentech terminated its partnership with UCB to develop the tau-targeting antibody bepranemab for Alzheimer’s disease.

UCB revealed the end of the deal...

Roche, via its Genentech subsidiary, paid $120m up front in July 2020 to partner on the development of bepranemab (UCB0107) with UCB, which stood to earn up to $2bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

More from Scrip

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.